Trial of Nemolizumab in Moderate-to-Severe Prurigo Nodularis
Open accessThe DOI matches its Crossref record; 18 of the 18 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Prurigo nodularis is a chronic pruritic skin disease with multiple nodular skin lesions. Nemolizumab is a monoclonal antibody targeting the interleukin-31 receptor, which is involved in the pathogenesis of prurigo nodularis. METHODS: We conducted a 12-week, randomized, double-blind, phase 2 trial of nemolizumab (at a dose of 0.5 mg per kilogram of body weight) administered subcutaneously at baseline, week 4, and week 8, as compared with placebo, in patients with moderate-to-severe prurigo nodularis and severe pruritus. Moderate-to-severe prurigo nodularis was defined as 20 or more nodules, and severe pruritus was defined as a mean score of at least 7 for the worst daily intensity of pruritus on the numerical rating scale (scores range from 0 [no itch] to 10 [worst itch imaginable]). The primary outcome was the percent change from baseline in the mean peak score for pruritus on the numerical rating scale at week 4. Secondary outcomes included additional measures of itching and disease severity. Safety assessments were performed through week 18. RESULTS: A total of 70 patients were randomly assigned in a 1:1 ratio to receive nemolizumab (34 patients) or placebo (36). The initial pruritus score on the numerical rating scale was 8.4 in each group. At week 4, the peak pruritus score on the numerical rating scale was reduced from baseline by 4.5 points (change, -53.0%) in the nemolizumab group, as compared with a reduction of 1.7 points (change, -20.2%) in the placebo group (difference, -32.8 percentage points; 95% confidence interval, -46.8 to -18.8; P<0.001). Results for secondary outcomes were in the same direction as for the primary outcome. Nemolizumab was associated with gastrointestinal symptoms (abdominal pain and diarrhea) and musculoskeletal symptoms. CONCLUSIONS: Nemolizumab resulted in a greater reduction in pruritus and severity of skin lesions than placebo in patients with prurigo nodularis but was associated with adverse events. Larger and longer trials are needed to determine the durability and safety of nemolizumab for the treatment of prurigo nodularis. (Funded by Galderma; ClinicalTrials.gov number, NCT03181503.).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Of note, nemolizumab generated promising results in prurigo nodularis, a highly pruritic skin disorder assumed to be related to AD193.”
From Atopic dermatitis: an expanding therapeutic pipeline for a complex disease (2022) · cites this paper as [193]
In the citing paper
“However, this conclusion may not be generalized for a number of itchy skin disorders such as prurigo nodularis in which targeting itch remains promising193,205,210–212.”
From Atopic dermatitis: an expanding therapeutic pipeline for a complex disease (2022) · cites this paper as [193]
Citations
Cites
IL-31: A new link between T cells and pruritus in atopic skin inflammation
Sonkoly, E., Muller, A., Lauerma, A. I., Pivarcsi, A., Soto, H., Kemeny, L., Alenius, H., Dieu-Nosjean, M.-C., Meller, S., Rieker, J., et al. (2006) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2005.10.033 · Cited by 1,005
Pereira, M. P., Steinke, S., Zeidler, C., Forner, C., Riepe, C., Augustin, M., Bobko, S., Dalgard, F., Elberling, J., Garcovich, S., et al. (2018) · Journal of the European Academy of Dermatology and Venereology · doi:10.1111/jdv.14570 · Cited by 274
Self-citationEthnic differences and comorbidities of 909 prurigo nodularis patients
Boozalis, E., Tang, O., Patel, S., Semenov, Y. R., Pereira, M. P., Stander, S., Kang, S., & Kwatra, S. G. (2018) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2018.04.047 · Cited by 189
Self-citationIL-31: A new key player in dermatology and beyond
Bağci, I. S., & Ruzicka, T. (2018) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2017.10.045 · Cited by 160
Chronic Prurigo of Nodular Type: A Review
Zeidler, C., Tsianakas, A., Pereira, M. P., Ständer, H. F., Yosipovitch, G., & Ständer, S. (2017) · Acta Dermato Venereologica · doi:10.2340/00015555-2774 · Cited by 126
Self-citationPrurigo Nodularis and Its Management
Zeidler, C., Yosipovitch, G., & Ständer, S. (2018) · Dermatologic Clinics · doi:10.1016/j.det.2018.02.003 · Cited by 112
Self-citationSteinke, S., Zeidler, C., Riepe, C., Bruland, P., Soto‐Rey, I., Storck, M., Augustin, M., Ивановна, Б. С., Garcovich, S., Legat, F. J., et al. (2018) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2018.04.044 · Cited by 104
Self-citationItch in dermatomyositis: the role of increased skin interleukin-31
Kim, H. J., Zeidi, M., Bonciani, D., Pena, S. M., Tiao, J., Sahu, S., & Werth, V. P. (2018) · British Journal of Dermatology · doi:10.1111/bjd.16498 · Cited by 94
The pathogenesis of Prurigo nodularis – ‘Super‐Itch’ in exploration
Zeidler, C., & Ständer, S. (2016) · European Journal of Pain · doi:10.1002/ejp.767 · Cited by 91
Self-citationBrenaut, E., Halvorsen, J. A., Dalgard, F. J., Lien, L., Balieva, F., Sampogna, F., Linder, D., Evers, A. W. M., Jemec, G. B. E., Gieler, U., et al. (2018) · Journal of the European Academy of Dermatology and Venereology · doi:10.1111/jdv.15145 · Cited by 85
Self-citation
Cited by
Items 201–281 of 281
Reich, A. (2021) · Journal of the European Academy of Dermatology and Venereology · doi:10.1111/jdv.17664 · Cited by 2
Self-citation[Translated article] Pruritus in Dermatology: Part 2—Diseases and Their Treatment
Navarro‐Triviño, F. J. (2023) · Actas Dermo-Sifiliográficas · doi:10.1016/j.ad.2023.06.007 · Cited by 4
Can Serum Biomarkers for Prurigo Nodularis Expose Pathophysiology or Just Treatment Response?
Kashem, S. W., & Fassett, M. S. (2023) · JAMA Dermatology · doi:10.1001/jamadermatol.2023.2608 · Cited by 2
Praktischer Umgang mit Pruritus im Alter
Witte, F., Zeidler, C., & Ständer, S. (2023) · Die Dermatologie · doi:10.1007/s00105-023-05207-5 · Cited by 2
“Auch Nemolizumab, ein subkutan applizierter Anti-Interleukin-31-Rezeptor-Antikörper, zeigt vielversprechende Effekte in der Reduktion des Pruritus und der Schwere der Läsionen, bei jedoch derzeit noch limitierender Verträglichkeit [38].”
Self-citationSinha, K., Sinha, T., Muppa, N., Kanwal, N., Blair, K., Chaudhari, S. S., Wei, C. R., & Amin, A. (2025) · Cureus · doi:10.7759/cureus.78761 · Cited by 3
“While all the included studies reported atopic dermatitis [9-12], only one study found a higher incidence of atopic dermatitis in the nemolizumab group than in the placebo group.”
InfluentialMahmoud, R. H., Coscarella, G., Kwak, R., & Yosipovitch, G. (2025) · Clinics in Dermatology · doi:10.1016/j.clindermatol.2025.03.011 · Cited by 3
Self-citationKeratin 17 is Not Always a Marker of Proliferation of Keratinocytes in Skin Diseases
Cui, L., Zhu, Z., Feng, Y., & Zhang, Y. (2021) · Clinical Cosmetic and Investigational Dermatology · doi:10.2147/ccid.s322226 · Cited by 2
“perivascular dense infiltrate with T cells, mast cells, eosinophil granulocytes, and expression of interleukin-31, which all promote epidermal hyperplasia.(11) In this work, K17 was not expressed in the hyperplastic epidermis, despite hyperplastic epidermis being a characteristic of LSC and PN.”
BackgroundChu, L., Shu, X., Wu, Y., Yang, H., Lu, Q., & Deng, H. (2022) · Frontiers in Physiology · doi:10.3389/fphys.2022.835269 · Cited by 2
“Prurigo nodularis (PN) is a chronic inflammatory skin disease characterized by multiple intensely pruritic, papulonodular lesions occurring in the background of intense pruritus with unknown causes, mechanisms and mediators (Sonkoly et al., 2006; Ständer et al., 2020).”
BackgroundRetractedBewley, A., & Taylor, R. E. (2024) · Wiley eBooks · doi:10.1002/9781119709268.rook084 · Cited by 2
Pruritus in the Elderly: Differential Diagnosis and Management
Shams, R. B., Lipner, M. B., & Sayed, C. J. (2024) · Current Geriatrics Reports · doi:10.1007/s13670-024-00418-7 · Cited by 1
Dai, R., Chi, C.-C., Lou, Y., Hsieh, I., & Man, X. (2025) · Dermatologic Therapy · doi:10.1155/dth/8988947 · Cited by 2
Li, B., Yao, W., Diao, R., Yang, B., Wang, Y., Li, T., Ge, L., & Wang, H. (2025) · International Medical Case Reports Journal · doi:10.2147/imcrj.s514339 · Cited by 3
“Nemolizumab as a humanized IL-31RA monoclonal antibody, shows a great reduction in pruritus and severity of skin lesions in patients with PN. 20,21 However, at the time of writing, nemolizumab is not available in China, and no registration filings have been checked, nor was it accessible to the…”
24-week real world outcomes of nemolizumab in patients with prurigo nodularis
Mima, Y., Yamamoto, M., & Iozumi, K. (2026) · Journal of Dermatological Treatment · doi:10.1080/09546634.2026.2624225 · Cited by 1
Somatic mutations reveal hyperactive Notch signaling in prurigo nodularis
Rajeh, A. A., Shahsavari, S., Cornman, H. L., Kollhoff, A. L., Gupta, A., Szeto, M. D., Kambala, A., Oladipo, O. O., Parthasarathy, V., Deng, J., et al. (2026) · JCI Insight · doi:10.1172/jci.insight.172371 · Cited by 1
“IL-31, a well-known pruritogenic cytokine, has also been implicated in M2-to-M1 polarization (64), linking Notch dysregulation, inflammatory cytokine release, and fibrosis in PN (65, 66).”
Aldamen, A. O., Alqahtani, R. A., Alqahtani, R., AlAnazi, Z. M., Almutairi, L. H., Alghatam, A. S., Alamari, A., Altamimi, I., Yadav, R., & Altamimi, A. (2026) · Annals of Medicine and Surgery · doi:10.1097/ms9.0000000000004973 · Cited by 1
“Nemolizumab also produced notable improvements in skin lesion severity, as reflected by IGA responses (RR: 4.06, 95% CI [2.42, 6.8], P 0.00001).”
InfluentialSystemic therapies for atopic dermatitis
Yousif, R., Elgindi, D., & Paller, A. S. (2026) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2026.01.075 · Cited by 2
Yosipovitch, G., Borkowska, K., Frampton, J., Schaible, K., Betts, M. B., Jack, K., Jabbar‐Lopez, Z. K., Neupane, B., Piketty, C., Subramanian, R., et al. (2026) · Dermatology and Therapy · doi:10.1007/s13555-026-01827-6 · Cited by 1
“…receptor alpha monoclonal antibody that was approved by the FDA in 2024 and by the EMA in 2025 for the treatment of PN. Phase 2 and 3 randomized clinical trials have suggested that nemolizumab can significantly reduce pruritus and improve the quality of life in patients with PN [6, 7].”
Self-citationLe prurit : de la physiopathologie à la thérapeutique
Misery, L. (2021) · Douleur et Analgésie · doi:10.3166/dea-2021-0160 · Cited by 1
Self-citationA New Era in the Management of Atopic Dermatitis
Golpanian, R. S., Gonzalez, J. M., & Yosipovitch, G. (2021) · Journal of the Dermatology Nurses’ Association · doi:10.1097/jdn.0000000000000634 · Cited by 1
“Nemolizumab, an anti-Il-31 antibody, as well as lebrikizumab and tralokinumab, which target IL-13, have all also been shown to show substantial, rapid improvements in AD and associated itch (Guttman-Yassky et al., 2020; Ständer et al., 2020; Wollenberg et al., 2019).”
BackgroundSelf-citationSpontaneous resolution of intractable prurigo nodularis after subinsular cortex stroke
Kashem, S. W., Motzkin, J. C., & Leslie, K. S. (2022) · JAAD Case Reports · doi:10.1016/j.jdcr.2022.12.008 · Cited by 1
“Monoclonal antibody against the IL-31 receptor, nemolizumab, has been shown to be effective in treating PN in a randomized clinical trial.(5) In addition, IL-31 may contribute to aberrant recruitment and proliferation of nerve fibers in the skin of”
MethodThe top 100 most cited contributions on prurigo nodularis: A bibliometric analysis
André, N., & Horev, A. (2023) · Clinics in Dermatology · doi:10.1016/j.clindermatol.2023.08.014 · Cited by 1
Brenaut, E., & Misery, L. (2023) · EMC - Tratado de Medicina · doi:10.1016/s1636-5410(23)48475-9 · Cited by 1
Self-citationPsychiatric Sequelae of Chronic Pruritic Dermatoses
Frasier, K. M., Li, V., Click, K., Dudzik, C. M., Sobotka, M. H., Rodriguez, E., & Stech, K. (2024) · Open Journal of Medical Psychology · doi:10.4236/ojmp.2024.132003 · Cited by 1
“Another pharmacologic intervention under recent clinical trials is nemolizumab, a monoclonal antibody that targets IL-31, which leads to a greater reduction in pruritus and a decreased severity of skin lesions [40].”
Yosipovitch, G., Ständer, S., Metz, M., Pink, A., Silverberg, J. I., Sofen, H. L., Ahmed, F., Noda, A., Jabbar‐Lopez, Z. K., Piketty, C., et al. (2024) · British Journal of Dermatology · doi:10.1093/bjd/ljae266.046 · Cited by 1
Self-citationEpidemiology of prurigo nodularis: An analysis of global trends from 1998–2023
Yang, S., Wang, C., Wang, S., Yu, Y., Cai, X., Wang, Y., & Li, X. (2025) · Clinical Epidemiology and Global Health · doi:10.1016/j.cegh.2024.101906 · Cited by 1
Zhao, X., Mueller, J. M., & Mueller, S. M. (2025) · Clinics in Dermatology · doi:10.1016/j.clindermatol.2025.03.005 · Cited by 2
Taiwanese Dermatological Association consensus for the diagnosis and management of prurigo nodularis
Lan, C.-C. E., Chung, W., Chen, Y., Hsiao, P., Hsiao, Y., Lee, C., Lin, T.-K., & Yang, H. (2025) · Dermatologica Sinica · doi:10.4103/ds.ds-d-24-00249 · Cited by 1
Arzneitherapie des chronischen Pruritus – Licht am Ende des langen Tunnels?
Pereira, M. P., Salzmann, S., Ständer, S., Staubach, P., & Metz, M. (2020) · Der Internist · doi:10.1007/s00108-020-00837-6 · Cited by 1
Self-citationIL-31 uncouples skin inflammation from itch sensation in allergic dermatitisPreprint
Fassett, M. S., Bráz, J. M., Castellanos, C. A., Schroeder, A., Sadeghi, M., Mar, D. J., Zhou, C. J., Shin, J., Basbaum, A. I., & Ansel, K. M. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.05.12.443916 · Cited by 1
“That dual expression pattern links skin inflammation with neurosensory pathways that mediate itch, and elevates IL-31 as a promising therapeutic target in a growing number of itchy inflammatory skin diseases including atopic dermatitis (AD)(3) and prurigo nodularis(4).”
BackgroundEndo, J. O., Peebles, J. K., & Lloyd, R. (2021) · Springer eBooks · doi:10.1007/978-3-030-76271-1_27 · Cited by 1
Somatic mutations reveal hyperactive Notch signaling and racial disparities in prurigo nodularisPreprint
Rajeh, A. A., Cornman, H. L., Gupta, A. K., Szeto, M. D., Kambala, A., Oladipo, O. O., Parthasarathy, V., Deng, J., Wheelan, S. J., Pritchard, T., et al. (2023) · medRxiv · doi:10.1101/2023.09.25.23295810 · Cited by 2
“The transition between M2 and 388 M1 macrophages is also induced by IL-31 (70), which helps connect Notch dysregulation, 389 inflammatory cytokine release, and itch propagation to tissue fibrosis (71, 72).”
BackgroundQuoi de neuf en thérapeutique dermatologique ?
Sbidian, É. (2020) · Annales de Dermatologie et de Vénéréologie · doi:10.1016/s0151-9638(20)31107-8
Besseres Krankheitsverständnis ermöglicht neue Therapien
Pereira, M. P., Salzmann, S., Ständer, S., Staubach, P., & Metz, M. (2021) · Der Deutsche Dermatologe · doi:10.1007/s15011-020-4461-6
“Kürzlich konnte in einer Phase-II-Studie gezeigt werden, dass Nemolizumab, ein monoklonaler IL-31-Rezeptor-A-Antagonist, zu einer erheblichen Verbesserung des Pruritus allgemein sowie der pruriginösen Läsionen bei Patienten mit chronischer Prurigo führt [25].”
BackgroundSelf-citationEsteves, C., Sylvié, M., García, S., Vannelli, M., & Aloise, Í. (2021) · Dermatología Argentina · doi:10.47196/da.v27i2.2077
El verbo hispánico, fundamentación pragmalingüística : (estudio de formantes)
Jiménez, D. J. (1999) · Universitat de València eBooks · Cited by 3
Prurigo nodularis, prurigo chronica, new therapeutic options
Bata‐Csörgõ, Z. (2021) · Bőrgyógyászati és Venerológiai Szemle · doi:10.7188/bvsz.2021.97.5.6
Klinische Dermatologie: Die Pipelines sind gefüllt
Frings, V. G., & Goebeler, M. (2021) · Deutsches Ärzteblatt · doi:10.3238/persderma.2021.06.18.01
Piletta‐Zanin, A., Hsieh, A., Mühlstädt, M., & Trigona, B. (2022) · JMIG · doi:10.53738/revmed.2022.18.767.156
Systemtherapie der atopischen Dermatitis
Werfel, T. (2022) · hautnah dermatologie · doi:10.1007/s15012-021-6825-3
Dermatoses inflammatoires et auto-immunes
Lenormand, C., Kluger, N., & Velter, C. (2022) · Annales de Dermatologie et de Vénéréologie - FMC · doi:10.1016/s2667-0623(22)00107-6 · Cited by 1
[Translated article] Update on Chronic Prurigo
Docampo‐Simón, A., Sánchez‐Pujol, M. J., & Salvador, J. F. S. (2022) · Actas Dermo-Sifiliográficas · doi:10.1016/j.ad.2022.04.007
Special aspects of prurigo nodularis diagnosis and treatment
Владимировна, З. Е., Евгеньевна, К. Д., Zvezdina, I. V., & Denisova, E. V. (2022) · Russian Journal of Clinical Dermatology and Venereology · doi:10.17116/klinderma202221051656
Heppt, F., Kiani, C. J., Preis, S., Schielein, M. C., Wecker, H., Ziehfreund, S., & Zink, A. (2023) · Elsevier eBooks · doi:10.1016/b978-3-437-23837-6.00007-1
Rôle de l’interleukine 31, une cytokine neuro-immune, dans le prurit et au-delà
Misery, L. (2023) · Annales de Dermatologie et de Vénéréologie - FMC · doi:10.1016/j.fander.2022.12.005
Self-citationQuel est le lien entre les maladies rares de la peau et notre pratique quotidienne?
Hohl, D. (2023) · Forum Médical Suisse ‒ Swiss Medical Forum · doi:10.4414/fms.2023.09271
Was verbindet seltene Hautkrankheiten mit unserer täglichen Praxis?
Hohl, D. (2023) · Swiss Medical Forum ‒ Schweizerisches Medizin-Forum · doi:10.4414/smf.2023.09271
Weber, M. B., Camozzato, F. O., & Recuero, J. K. (2023) · Springer eBooks · doi:10.1007/978-3-031-13505-7_67 · Cited by 2
Vielversprechende neue Therapien
Pereira, M. P., & Metz, M. (2023) · Deutsche Dermatologie · doi:10.1007/s15011-023-5824-6
Pereira, M. P., & Metz, M. (2023) · Die Dermatologie · doi:10.1007/s00105-023-05222-6
Reich, A., & Szepietowski, J. C. (2023) · Springer eBooks · doi:10.1007/978-3-031-15130-9_77
Self-citationCurrent approaches to the treatment of prurigo in adults
Krasil’nikova, E. S., Zainullina, O. N., & Hismatullina, Z. R. (2023) · Russian Journal of Clinical Dermatology and Venereology · doi:10.17116/klinderma202322051524
Triple-Therapy for Prurigo Nodularis: A Case ReportPreprint
Carver, C., Shah, S. H., & Ahmed, N. (2023) · doi:10.22541/au.169986096.64745299/v1
Quoi de neuf en thérapeutique dermatologique ?
Samimi, M. (2023) · Annales de Dermatologie et de Vénéréologie - FMC · doi:10.1016/s2667-0623(23)01012-7
Wu, H.-H., & You, Y. (2023) · International Journal of Dermatology and Venereology · doi:10.1097/jd9.0000000000000364
Pruritus, Prurigo and Lichen Simplex
Ständer, S., & Yosipovitch, G. (2024) · Wiley eBooks · doi:10.1002/9781119709268.rook081 · Cited by 2
Self-citationTargeted Biologic Therapies in Chronic Prurigo: The Evolving Landscape of Chronic Prurigo Treatment
Stefaniak, A. A., & Szepietowski, J. C. (2024) · Current Pharmaceutical Design · doi:10.2174/0113816128300373240514072201
Thünemann, J., Müller, S., Steinbrink, K., Ständer, S., & Zeidler, C. (2024) · JDDG Journal der Deutschen Dermatologischen Gesellschaft · doi:10.1111/ddg.15317_g
Self-citationAktivatoren von KNa1.1-Kanälen für die Therapie von Schmerz und Pruritus
Balzulat, A. (2024) · Publication Server of Goethe University Frankfurt am Main (Goethe University Frankfurt) · doi:10.21248/gups.86142
Prurigo de Hyde e as opções de tratamento com anticorpos monoclonais: uma revisão narrativa
de Araújo, R. J. O., de Figueiredo, L. R. D. M. P., Vieira, M. D. C. P., de Macedo, A. V. L. B., & Mendes, A. H. S. (2024) · RAMB Revista da Associação Médica Brasileira Junior Doctors · doi:10.5327/2965-0682-20245208
Abdelwahab, S. İ., Farasani, A. M., Alfaifi, H. A., Alamer, A. S., Altherwi, T. I., Alshahrani, S., Assiri, A., & Hassan, W. (2024) · Clinics in Dermatology · doi:10.1016/j.clindermatol.2024.11.004
Song, J., Yang, J., Yan, Y., Liu, T., Fan, J., & Jiao, H. (2025) · Aesthetic Plastic Surgery · doi:10.1007/s00266-025-04692-4
“Recently, inhibitors targeting IL-31RA (nemoli-zumab) [19] and OSMR b (vixarelimab, also known as KPL-716) [20] have shown promise in reducing pruritus and skin inflammation associated with prurigo nodularis.”
Breaking the itch cycle: long-term effects of nemolizumab in prurigo nodularis
Kędra, K., & Reich, A. (2025) · British Journal of Dermatology · doi:10.1093/bjd/ljaf093
Self-citationNemolizumab Treatment Normalizes Dysregulated Microbiome in Lesional Prurigo Nodularis
Zhou, R., Chaskar, P., Patrick, M. T., Wang, K., Piketty, C., Julia, V., Gudjonsson, J. E., Krishnaswamy, J. K., & Tsoi, L. C. (2025) · Journal of Investigative Dermatology · doi:10.1016/j.jid.2025.06.1575
Self-citationAging and Itch: A Short Review on Geriatric Pruritus
Gupta, S. (2025) · Journal of The Indian Academy of Geriatrics · doi:10.4103/jiag.jiag_9_25
Vieira, A. C. P., Akabane, M. A. C. C., Caletti, G. C. G., Heffel, K. K., & Silva, A. T. O. E. (2025) · Anais Brasileiros de Dermatologia (Versão em Português) · doi:10.1016/j.abdp.2025.501210
Prurigo nodularis en plaque resolved after a loading dose of nemolizumab
Cho, S. W., Chen, H., Chen, A., Sontam, T. R., & Tarbox, M. B. (2025) · Baylor University Medical Center Proceedings · doi:10.1080/08998280.2025.2605613
Misery, L. (2026) · EMC - Dermatologie · doi:10.1016/s0246-0319(25)50308-4
Self-citationStänder, S., Yang, M., Martins, B., Liu, J., Zion, A., Bosman, K., Zahn, J., Thomas, R. B., & Bahloul, D. (2026) · Journal of Dermatological Treatment · doi:10.1080/09546634.2026.2623403
Self-citationTargeting the neuroimmune axis in prurigo nodularis: a critical appraisal of the nemolizumab trials
Lernia, V. G. D., & Sticchi, A. (2026) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2026.2635517
“The threshold of 20 or more nodules is widely accepted to distinguish moderate-to-severe cases warranting systemic therapy from mild cases manageable with topical treatments [11].”
Ling, S., Liao, Y. S. J., Chen, C., Wu, R., Yin, M., Wei, L., Chen, J., Huang, H., & Dou, X. (2026) · Frontiers in Allergy · doi:10.3389/falgy.2026.1769768
“Recent phase 3 clinical trials have demonstrated that IL-4/IL-13 pathway blockade and IL-31 receptor blockade can significantly improve pruritus and nodule severity in PN (29–32).”
Neuroimmune interactions in itch
Deng, L., & Chiu, I. M. (2026) · Elsevier eBooks · doi:10.1016/b978-0-443-34172-4.00007-0
Chronic nodular prurigo/prurigo nodularis
Royeck, S., Zeidler, C., Wiegmann, H., & Ständer, S. (2026) · Elsevier eBooks · doi:10.1016/b978-0-443-34172-4.00027-6
Self-citationGönüllü, Ö., Erdem, O., Özkanlı, S. Ş., Atış, G., & Gürel, M. S. (2026) · Journal of Cutaneous Pathology · doi:10.1111/cup.70115
Misery, L. (2026) · EMC - Dermatología · doi:10.1016/s1761-2896(26)51745-x
Self-citationSwiss Practice Recommendations for Chronic Prurigo Including Prurigo Nodularis
Mueller, S. M., Beltraminelli, H., Boehncke, W., Böhm, M., Cozzio, A., Häusermann, P., Jalili, A., Kolios, A. G. A., Lang, C. C. V., Loos, E. F., et al. (2026) · International Journal of Dermatology · doi:10.1111/ijd.70533
Soenoe, M. S., & Hadi, S. (2026) · Archives of Dermatological Research · doi:10.1007/s00403-026-04760-y
“Specifically, only four of the six trials actually enrolled patients with atopic dermatitis, whereas the remaining two investigated different clinical populations—one involving uremic pruritus (Kinugasa E et al. [18]) and another examining prurigo nodularis (Ständer S et al. [19 ]).”
Misery, L. (2026) · Elsevier eBooks · doi:10.1016/b978-2-294-77608-3.00140-x
Self-citationLiu, Y., Hu, H., & Li, L. (2026) · Journal of Dermatological Treatment · doi:10.1080/09546634.2026.2739090
Yu, Y., Li, S., Chen, W., & Chen, X. (2026) · Frontiers in Medicine · doi:10.3389/fmed.2026.1942040
Gill, O. A., Shawwa, A., Alhamwi, N., Saleh, A. O., Gill, M. U., Rahim, M. W., Chaudary, M., & Lapenda, I. (2026) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/s00210-026-06028-8
Metadata
- Authors
- Ständer, S., Yosipovitch, G., Legat, F. J., Lacour, J.-P., Paul, C., Narbutt, J., Bieber, T., Misery, L., Wollenberg, A., Reich, A., Ahmad, F., & Piketty, C.
- Affiliations
- University Hospital Bonn (DE)
- University of Graz (AT)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2020-02-20
- Volume
- 382
- Issue
- 8
- Pages
- 706-716
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W3008008049
- Cited by
- 281
- References
- 18
- Citations by year
- 2026: 22 · 2025: 36 · 2024: 39 · 2023: 63 · 2022: 40 · 2021: 52 · 2020: 28
- FWCI
- 33.42
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Nestle Skin Health
- Topics
- Health Sciences › Medicine › Dermatology › Dermatology and Skin Diseases
- Life Sciences › Immunology and Microbiology › Immunology › Psoriasis: Treatment and Pathogenesis
- Health Sciences › Medicine › Dermatology › Cutaneous lymphoproliferative disorders research
- Keywords
- prurigo nodularis, nemolizumab, monoclonal antibodies, pruritus, skin lesions, adverse events, gastrointestinal symptoms, musculoskeletal symptoms, treatment safety, treatment efficacy, numerical rating scale
- MeSH terms
- Adult, Aged, Aged, 80 and over, Double-Blind Method, Female, Gastrointestinal Diseases, Humans, Injections, Subcutaneous, Male, Middle Aged, Muscular Diseases, Prurigo, Pruritus, Young Adult, Antibodies, Monoclonal, Humanized, Patient Acuity
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.